Zenara Pharma launches first generic of Paxlovid for COVID-19 in India

The product will be sold at a Maximum Retail Price of Rs 5,200 per box, equivalent to one full course of treatment per patient.

Zenara Pharma launches first generic of Paxlovid for COVID-19 in India
Zenara Pharma launches first generic of Paxlovid for COVID-19 in India
  • First company to launch the product in the country
  • Reduces the risk of death or hospitalization by 89%*
  • Pfizer’s Paxlovid is approved by US FDA for COVID treatment

 

Hyderabad-based Zenara Pharma, a fully owned subsidiary of Biophore India Pharmaceuticals, has announced that it has launched Nirmatrelvir and Ritonavir tablets in a combi pack as a treatment option for patients with mild to moderate symptoms of Covid-19. It is to be noted that Zenara Pharma has received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market this product last month. The tablet, which will be sold under the brand name ‘Paxzen’, is being manufactured at Zenara’s US FDA and EU approved state-of-the-art facility in Hyderabad.

The product will be sold at a Maximum Retail Price of Rs 5,200 per box, equivalent to one full course of treatment per patient, and contains 20 Tablets of Nirmatrelvir 150ml and 10 Tablets of Ritonavir 100mg.

Dr. Jagadeesh Babu Rangisetty, Co-founder and Managing Director at Zenara Pharma, says, “We have launched this product in India with an aim to bring the best treatment options against COVID within reach of patients in our country. Our product, Paxzen, has been proven equivalent to Paxlovid through a Bio Equivalence study, based on which we have received the approval from the regulatory authorities”

This product’s breakthrough approval in the US was given by the US FDA in Dec 2021 and is indicated for the treatment of mild-to-moderate COVID-19 in adults. It was the first oral pill that has been approved by US FDA and with a better safety profile than subsequently approved oral therapies and can be self-administered at home, when prescribed. Studies also indicate that the risk of death or hospitalization is reduced by 89%* when taken in a timely manner against COVID.

 

Dr Rangisetty adds, “We have ensured that the product will be available to all patients by placing the product with our distribution partners spread across India and their details can be accessed through our dedicated help line number – 72079 28889 and also through our website. Patients or hospitals may call or whatsapp on this number for availability and we will ensure that they can access Paxzen at the earliest.”

Zenara has informed that patients or hospitals may contact this dedicated help line number – 72079 28889  or visit their website www.zenarapharma.com for availability details of Paxzen in their vicinity.

About Zenara Pharma:

Zenara Pharma Pvt Ltd is a Hyderabad based formulation manufacturing company, focused on serving markets with high quality and reliable pharmaceutical products. The product portfolio primarily consists of Tablets and Capsules, with capabilities to manufacture oral solutions as well. The manufacturing facility has been inspected and approved by the US FDA and EU authorities, along with WHO GMP certification.